Initiator Pharma reports positive final Phase IIa data for IPED2015
Initiator Pharma A/S, a clinical-stage biotech company that is developing a novel treatment of severe erectile dysfunction (sED), today announced the final data from the company’s Phase IIa study with IPED2015, demonstrating statistically significant and clinically relevant results on key efficacy endpoints in patients with sED after a single administration of IPED2015. As previously reported, the Phase IIa study was completed satisfactorily with no observations of critical adverse events.The Phase IIa Proof-of-Concept study was designed as an exploratory trial and included twelve patients